{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:48:35Z","timestamp":1784177315837,"version":"3.55.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Octogenarians represent a significant fraction of patients with chronic lymphocytic leukemia (CLL) but, despite the prevalence of the disease in this age group, limited data are available on the safety and efficacy of novel drugs in this subgroup. We conducted a multicenter retrospective study enrolling 120 octogenarian patients who received venetoclax (Ven) regimens in any line. Regarding efficacy, we found Ven to perform similarly to what is reported in younger patients with CLL, with an overall response rate of 91%, a complete response rate of 44%, and median progression-free survival of 44 months. Concerning safety, we report a toxicity profile that is consistent with previous reports, with most high-grade adverse events being of hematologic or infectious nature, given that 37% and 22% of patients experienced neutropenia or infections of grade 3 or higher. As part of our study, we compared the safety and efficacy data we collected with those obtained in a comparable Bruton tyrosine kinase inhibitor (BTKi)-treated population. We found that these 2 treatments were comparable in terms of overall efficacy, barring a higher rate of complete responses with Ven; safety profiles were different among the 2 groups given that BTKi-treated patients had more cardiovascular toxicities (26% vs 4%) and Ven-treated subjects experienced more infectious events (82% vs 49%). Our data point out that Ven-based regimens are safe and effective in octogenarian patients with CLL despite their higher clinical complexity and comorbidity burden and should provide some basis for the design of prospective studies to further evaluate the optimal treatment regimen in this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015818","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:12:55Z","timestamp":1744816375000},"page":"3576-3584","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1482-4350","authenticated-orcid":false,"given":"Andrea","family":"Serafin","sequence":"first","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1094-9992","authenticated-orcid":false,"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"2Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mazzetto","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-2573","authenticated-orcid":false,"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-7901","authenticated-orcid":false,"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Azienda socio sanitaria territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"4Hematology and Transplant Unit, Azienda ospedaliero universitaria Santi Antonio e Biagio, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sanna","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Department of Oncology, Azienda ospedaliero universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-846X","authenticated-orcid":false,"given":"Costantino","family":"Riemma","sequence":"additional","affiliation":[{"name":"7IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d - IRST, Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cibien","sequence":"additional","affiliation":[{"name":"8Hematology Unit, Ca\u2019Foncello Hospital, Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Noto","sequence":"additional","affiliation":[{"name":"9Hematology Unit, Fondazione Istituto di ricovero e cura a carattere scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Lista","sequence":"additional","affiliation":[{"name":"10Hematology Unit, Santa Chiara Hospital, Azienda provinciale per i servizi sanitari, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Foglietta","sequence":"additional","affiliation":[{"name":"11Hematology Unit, Santa Croce e Carle General Hospital, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-8724","authenticated-orcid":false,"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[{"name":"12Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, Azienda ospedaliero universitaria, Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Innao","sequence":"additional","affiliation":[{"name":"13Unit\u00e0 Operativa Complessa di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bullo","sequence":"additional","affiliation":[{"name":"14Hematology Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lovato","sequence":"additional","affiliation":[{"name":"15Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8335","authenticated-orcid":false,"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[{"name":"15Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Andriola","sequence":"additional","affiliation":[{"name":"16Hematology, Department of Translational and Precision Medicine, \u201cSapienza\u201d University, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ballotta","sequence":"additional","affiliation":[{"name":"17Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[{"name":"18Dipartimento di Diagnosi per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli Istituto di ricovero e cura a carattere scientifico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9009","authenticated-orcid":false,"given":"Alberto","family":"Fresa","sequence":"additional","affiliation":[{"name":"18Dipartimento di Diagnosi per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli Istituto di ricovero e cura a carattere scientifico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Favrin","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Fondazione Istituto di ricovero e cura a carattere scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Fondazione Istituto di ricovero e cura a carattere scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Santambrogio","sequence":"additional","affiliation":[{"name":"20Hematology Unit, Azienda ospedaliero universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[{"name":"20Hematology Unit, Azienda ospedaliero universitaria Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-8883","authenticated-orcid":false,"given":"Raffaella","family":"Pasquale","sequence":"additional","affiliation":[{"name":"21Hematology Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Moratti","sequence":"additional","affiliation":[{"name":"21Hematology Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"18Dipartimento di Diagnosi per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli Istituto di ricovero e cura a carattere scientifico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-7675","authenticated-orcid":false,"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[{"name":"12Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, Azienda ospedaliero universitaria, Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[{"name":"22Institute of Hematology, Center for Hemato-Oncological Research, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"23Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[{"name":"16Hematology, Department of Translational and Precision Medicine, \u201cSapienza\u201d University, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"24Oncohematology Unit, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-8140","authenticated-orcid":false,"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"25Division of Onco-Hematology, Istituto europeo di oncologia, European Institute of Oncology Istituto di ricovero e cura a carattere scientifico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-0989","authenticated-orcid":false,"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"26Strategic Research Program on Chronic Lymphocytic Leukemia, Istituto di ricovero e cura a carattere scientifico Ospedale San Raffaele, Milano, Italy"},{"name":"27Medical School, Universit\u00e0 Vita-Salute San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"26Strategic Research Program on Chronic Lymphocytic Leukemia, Istituto di ricovero e cura a carattere scientifico Ospedale San Raffaele, Milano, Italy"},{"name":"27Medical School, Universit\u00e0 Vita-Salute San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-1308","authenticated-orcid":false,"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"28Hematology Section, Department of Medical Sciences, Azienda Ospedaliera-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Azienda socio sanitaria territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6149","authenticated-orcid":false,"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"2Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy"},{"name":"29Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Department of Medicine, University of Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2025072114013202600_bib1","unstructured":"National Cancer Institute\n          . Cancer Stat Facts: Leukemia \u2014 Chronic Lymphocytic Leukemia (CLL). Accessed 12 November 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"2025072114013202600_bib2","unstructured":"Cancer Research UK\n          . Chronic lymphocytic leukaemia (CLL) incidence statistics. Accessed 12 November 2024. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-cll\/incidence."},{"issue":"10","key":"2025072114013202600_bib3","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/ijc.27889","article-title":"Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France","volume":"132","author":"Monnereau","year":"2013","journal-title":"Int J Cancer"},{"issue":"10129","key":"2025072114013202600_bib4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"The Lancet"},{"issue":"25","key":"2025072114013202600_bib5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2025072114013202600_bib6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025072114013202600_bib7","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"22","key":"2025072114013202600_bib8","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025072114013202600_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025072114013202600_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"10232","key":"2025072114013202600_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"2025072114013202600_bib12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2025072114013202600_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/bloodadvances.2022007619","article-title":"Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort","volume":"7","author":"Reda","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025072114013202600_bib14","doi-asserted-by":"crossref","first-page":"e3249","DOI":"10.1002\/hon.3249","article-title":"Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort","volume":"42","author":"Martino","year":"2024","journal-title":"Hematol Oncol"},{"key":"2025072114013202600_bib15","doi-asserted-by":"crossref","first-page":"1033413","DOI":"10.3389\/fonc.2022.1033413","article-title":"Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study","volume":"12","author":"Visentin","year":"2022","journal-title":"Front Oncol"},{"issue":"17","key":"2025072114013202600_bib16","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model","volume":"27","author":"Gordon","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2025072114013202600_bib17","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/blood-2024-200848","article-title":"Efficacy and safety of acalabrutinib treatment in very old (\u226580y) and\/or frail patients with chronic lymphocytic leukemia (CLL) - primary endpoint analysis of the phase II CLL-Frail trial","volume":"144","author":"Simon","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025072114013202600_bib18","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [published correction appears in Blood. 2008;112(13):5259]","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2025072114013202600_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2025072114013202600_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025072114013202600_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2025072114013202600_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2025072114013202600_bib23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2021.278304","article-title":"The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation","volume":"107","author":"Visentin","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"2025072114013202600_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/cancers16061095","article-title":"Chronic lymphocytic leukemia (CLL) with borderline immunoglobulin heavy chain mutational status, a rare subgroup of CLL with variable disease course","volume":"16","author":"Angotzi","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025072114013202600_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.19517","article-title":"Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens","volume":"205","author":"Serafin","year":"2024","journal-title":"Br J Haematol"},{"issue":"9","key":"2025072114013202600_bib26","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/era.10.127","article-title":"Chronic lymphocytic leukemia: planning for an aging population","volume":"10","author":"Gribben","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025072114013202600_bib27","doi-asserted-by":"crossref","first-page":"20406207221127550","DOI":"10.1177\/20406207221127550","article-title":"Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia","volume":"13","author":"Frustaci","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"2025072114013202600_bib28","volume-title":"Package insert","author":"Venetoclax","year":"2018"},{"issue":"1","key":"2025072114013202600_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"9","key":"2025072114013202600_bib30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2025072114013202600_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hon.3122","article-title":"Real-world evidence on venetoclax in chronic lymphocytic leukemia: the Italian experience","volume":"41","author":"Laurenti","year":"2023","journal-title":"Hematol Oncol"},{"issue":"5","key":"2025072114013202600_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.15604","article-title":"Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia","volume":"183","author":"Al-Sawaf","year":"2018","journal-title":"Br J Haematol"},{"issue":"14","key":"2025072114013202600_bib33","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1080\/10428194.2022.2123223","article-title":"Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older","volume":"63","author":"Simon","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025072114013202600_bib34","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.16271","article-title":"The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia","volume":"188","author":"Eyre","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3576\/2402640\/blooda_adv-2025-015818-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3576\/2402640\/blooda_adv-2025-015818-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T18:01:41Z","timestamp":1753120901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3576\/536749\/Venetoclax-based-regimens-in-octogenarian-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":34,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015818","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,11]]}}}